Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: Results of a prospective trial from the National Marrow Donor Program

Blood

Volumn 121, Issue 1, 2013, Pages 197-206

  Pulsipher, Michael A ^a   Chitphakdithai, Pintip ^b   Logan, Brent R ^c   Shaw, Bronwen E ^d   Wingard, John R ^e   Lazarus, Hillard M ^f   Waller, Edmund K ^g   Seftel, Matthew ^h   Stroncek, David F ⁱ   Lopez, Angela M ^j   Maharaj, Dipnarine ^k   Hematti, Peiman ^l   O'Donnell, Paul V ^m   Loren, Alison W ⁿ   Leitman, Susan F ⁱ   Anderlini, Paolo ^o   Goldstein, Steven C ^p   Levine, John E ^p   Navarro, Willis H ^b,q   Miller, John P ^q   Confer, Dennis L ^b,q   more..

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

^e LifeSouth Community Blood Centers   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g EMORY UNIVERSITY HOSPITAL   (United States)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k Bethesda Health City   (United States)

^l University of Wisconsin Health   (United States)

^m Fred Hutchinson Cancer Research Center   (United States)

ⁿ HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^o UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^p UNIVERSITY OF MICHIGAN   (United States)

^q NATIONAL MARROW DONOR PROGRAM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE TOXICITY; ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD CELL COUNT; BLOOD TOXICITY; BONE PAIN; CONTROLLED STUDY; CONVALESCENCE; DIZZINESS; DONOR; FATIGUE; FEMALE; FEVER; GROUPS BY AGE; HEADACHE; HEMATOPOIETIC STEM CELL; HIP PAIN; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; LIMB PAIN; MALE; MYALGIA; NAUSEA; NECK PAIN; OBESITY; PAIN ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEX DIFFERENCE; SORE THROAT; STEM CELL MOBILIZATION;

EID: 84872059501     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-417667     Document Type: Article

References (23)

1. Miller JP, Perry EH, Price TH, et al. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008;14(9 Suppl):29-36.
2. King RJ, Confer DL, Greinix HT, et al. Unrelated hematopoietic stem cell donors as research subjects. Bone Marrow Transplant. 2011;46(1):10-13.
3. Shaw BE, Ball L, Beksac M, et al. Donor safety: the role of the WMDAin ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. Bone Marrow Transplant. 2010;45(5):832-838.
4. Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009;113(15):3604-3611.
5. Switzer GE, Harrington D, Haagenson MD, et al. Health-related quality-of-life among adult matched unrelated stem cell donors: a Blood and Marrow Transplant Clinical Trials Network (BMT CTN) randomized trial of marrow versus PBSC donation [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):165. Abstract 366.
6. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations J Am Stat Assoc. 1958;53:457-481.
7. Cox D. Regression models and life tables. J R Stat Soc B. 1972;34:187-202.
8. Favre G, Beksac M, Bacigalupo A, et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant. 2003;32(9):873-880.
9. Bredeson C, Leger C, Couban S, et al. An evaluation of the donor experience in the Canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol Blood Marrow Transplant. 2004;10(6):405-414.
10. Fortanier C, Kuentz M, Sutton L, et al. Healthy sibling donor anxiety and pain during bone marrow or peripheral blood stem cell harvesting for allogeneic transplantation: results of a randomised study. Bone Marrow Transplant. 2002;29(2):145-149.
11. Heldal D, Brinch L, Tjonnfjord G, et al. Donation of stem cells from blood or bone marrow: results of a randomised study of safety and complaints. Bone Marrow Transplant. 2002;29(6):479-486.
12. Kennedy GA, Morton J, Western R, Butler J, Daly J, Durrant S. Impact of stem cell donation modality on normal donor quality of life: a prospective randomized study. Bone Marrow Transplant. 2003;31(11):1033-1035.
13. Rowley SD, Donaldson G, Lilleby K, Bensinger WI, Appelbaum FR. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood. 2001;97(9):2541-2548.
14. Siddiq S, Pamphilon D, Brunskill S, Doree C, Hyde C, Stanworth S. Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors. Cochrane Database Syst Rev. 2009;(1):CD006406.
15. Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant. 2000;25(1):85-89.
16. Anderlini P, Chan FA, Champlin RE, Korbling M, Strom SS. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant. 2002;30(10):661-663.
17. Storek J, Dawson MA, Maloney DG. Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting. Blood. 2000;95(9):2993-2994.
18. Marmier-Savet C, Larosa F, Legrand F, et al. Persistence of lymphocyte function perturbations after granulocyte-colony-stimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors. Transfusion. 2010;50(12):2676-2685.
19. McCullough J, Kahn J, Adamson J, et al. Hematopoietic growth factors - use in normal blood and stem cell donors: clinical and ethical issues. Transfusion. 2008;48(9):2008-2025.
20. Pamphilon D, Nacheva E, Navarrete C, Madrigal A, Goldman J. The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion. 2008;48(7):1495-1501.
21. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer. 2006;46(4):422-433.
22. Confer DL, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol. 2007;137(1):77-78; author reply 79-80.
23. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008;112(4):990-998.